Progressive lung cancer is associated with abnormal coagulation. Platelets play a vital part in evading immune surveillance and angiogenesis in the case of tumor metastasis. The study aimed to analyze the predictive and prognostic effects of platelet count on non-small cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). This study retrospectively analyzed the prognostic effects of platelets on 52 NSCLC patients with epidermal growth factor receptor (EGFR) mutant following EGFR-TKI treatment. Related data, together with the progression-free survival (PFS) and overall survival (OS) were collected before and after 2 cycles of treatments (60 days). The anti-EGFR treatment markedly reduced the platelet count in 33 (63.5%) patients after 2 cycles of treatment. Multivariate Cox analysis revealed that, the decreased platelet count was closely correlated with the longer OS (HR = 0.293; 95%CI: 0.107-0.799; p = 0.017). Besides, the median OS was 326 days in the decreased platelet count group and 241 days in the increased platelet count group (HR = 0.311; 95%CI: 0.118-0.818; P = 0.018), as obtained from the independent baseline platelet levels and other clinical features. The platelet count may predict the prognosis for EGFR-TKI treatment without additional costs. Besides, changes in platelet count may serve as a meaningful parameter to establish the prognostic model for NSCLC patients receiving anti-EGFR targeted therapy.

中文翻译：

---

血小板减少对EGFR-TKI治疗非小细胞肺癌患者预后的影响：一项回顾性研究

进行性肺癌与凝血异常有关。在肿瘤转移的情况下，血小板在逃避免疫监视和血管生成中起着至关重要的作用。该研究旨在分析血小板计数对使用表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）治疗的非小细胞肺癌（NSCLC）患者的预测和预后影响。这项研究回顾性分析了血小板对EGFR-TKI治疗后的52例具有表皮生长因子受体（EGFR）突变的NSCLC患者的预后影响。在治疗的两个周期（60天）之前和之后，收集了相关数据以及无进展生存期（PFS）和总体生存期（OS）。2个疗程后，抗EGFR治疗显着降低了33名患者（63.5％）的血小板计数。多元Cox分析显示，血小板计数减少与较长的OS密切相关（HR = 0.293； 95％CI：0.107-0.799； p = 0.017）。此外，血小板计数减少组的中位OS为326天，血小板计数增加组的中位OS为241天（HR = 0.311； 95％CI：0.118-0.818； P = 0.018），这是根据独立的基线血小板水平和其他临床特征。血小板计数可以预测EGFR-TKI治疗的预后，而无需额外费用。此外，血小板计数的变化可以作为建立抗EGFR靶向治疗的NSCLC患者预后模型的有意义的参数。血小板减少计数组的中位OS为326天，血小板增加计数组的中位OS为241天（HR = 0.311； 95％CI：0.118-0.818； P = 0.018），这是根据独立的基线血小板水平和其他临床指标得出的特征。血小板计数可以预测EGFR-TKI治疗的预后，而无需额外费用。此外，血小板计数的变化可以作为建立抗EGFR靶向治疗的NSCLC患者预后模型的有意义的参数。血小板减少计数组的中位OS为326天，血小板增加计数组的中位OS为241天（HR = 0.311； 95％CI：0.118-0.818； P = 0.018），这是根据独立的基线血小板水平和其他临床指标得出的特征。血小板计数可以预测EGFR-TKI治疗的预后，而无需额外费用。此外，血小板计数的变化可以作为建立抗EGFR靶向治疗的NSCLC患者预后模型的有意义的参数。